New pill combo may boost rectal cancer remission before surgery
NCT ID NCT06850090
First seen May 04, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests whether a newer oral chemotherapy drug (TAS-102) works better than the current standard (capecitabine) when given with radiation before surgery for locally advanced rectal cancer. About 210 adults aged 18-75 with stage II or III rectal cancer will take part. The goal is to see if TAS-102 leads to more complete tumor disappearance before surgery, while keeping side effects manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.